| Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria P Urquiza, A Laín, A Sanz-Parra, J Moreno, G Bernardo-Seisdedos, ... Science translational medicine 10 (459), eaat7467, 2018 | 58 | 2018 |
| Abnormal concentration of porphyrins in serum from COVID‐19 patients I San Juan, C Bruzzone, M Bizkarguenaga, G Bernardo‐Seisdedos, ... British journal of haematology 190 (5), e265, 2020 | 39 | 2020 |
| Glycoprofile analysis of an intact glycoprotein as inferred by NMR spectroscopy L Unione, MP Lenza, A Ardá, P Urquiza, A Laín, JM Falcón-Pérez, ... ACS central science 5 (9), 1554-1561, 2019 | 37 | 2019 |
| Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition JM Blouin, G Bernardo-Seisdedos, E Sasso, J Esteve, C Ged, M Lalanne, ... Human molecular genetics 26 (8), 1565-1576, 2017 | 32 | 2017 |
| Mitochondrial inorganic polyphosphate (polyP) is a potent regulator of mammalian bioenergetics in SH-SY5Y cells: a proteomics and metabolomics study M Guitart-Mampel, P Urquiza, F Carnevale Neto, JR Anderson, ... Frontiers in Cell and Developmental Biology 10, 833127, 2022 | 25 | 2022 |
| Enzymatic depletion of mitochondrial inorganic polyphosphate (polyP) increases the generation of reactive oxygen species (ROS) and the activity of the pentose phosphate pathway … V Hambardikar, M Guitart-Mampel, ER Scoma, P Urquiza, GGA Nagana, ... Antioxidants 11 (4), 685, 2022 | 24 | 2022 |
| Is there a link between inorganic polyphosphate (polyP), mitochondria, and neurodegeneration? EA Borden, M Furey, NJ Gattone, VD Hambardikar, XH Liang, ER Scoma, ... Pharmacological research 163, 105211, 2021 | 24 | 2021 |
| Impact of aldosterone on the failing myocardium: insights from mitochondria and adrenergic receptors signaling and function M Guitart-Mampel, P Urquiza, JI Borges, A Lymperopoulos, ME Solesio Cells 10 (6), 1552, 2021 | 16 | 2021 |
| Human prune regulates the metabolism of mammalian inorganic polyphosphate and bioenergetics ER Scoma, RT Da Costa, HH Leung, P Urquiza, M Guitart-Mampel, ... International journal of molecular sciences 24 (18), 13859, 2023 | 7 | 2023 |
| Improving the pharmacological properties of ciclopirox for its use in congenital erythropoietic porphyria G Bernardo-Seisdedos, JM Charco, I SanJuan, S García-Martínez, ... Journal of Personalized Medicine 11 (6), 485, 2021 | 7 | 2021 |
| Mitochondrial inorganic polyphosphate is required to maintain proteostasis within the organelle RT Da Costa, P Urquiza, MM Perez, YG Du, ML Khong, H Zheng, ... Frontiers in Cell and Developmental Biology 12, 1423208, 2024 | 2 | 2024 |
| Toolkit for cellular studies of mammalian mitochondrial inorganic polyphosphate V Hambardikar, YA Akosah, ER Scoma, M Guitart-Mampel, P Urquiza, ... Frontiers in Cell and Developmental Biology 11, 1302585, 2023 | 2 | 2023 |
| New pharmacological therapies against congenital erythropoietic porphyria (CEP) PD Urquiza, A Lain, A Sanz, JM Falcon, O Millet Protein Science 24, 64-64, 2015 | 2 | 2015 |
| Inorganic polyphosphate, mitochondria, and neurodegeneration P Urquiza, ME Solesio Inorganic Polyphosphates: From Basic Research to Medical Application, 27-49, 2022 | 1 | 2022 |
| Role of mitochondrial inorganic polyphosphate in maintaining mammalian bioenergetics and redox balance, by the regulation of the pentose phosphate pathway VD Hambardikar, MG Mampel, P Urquiza, E Scoma, J Collins, M Solesio Biophysical Journal 121 (3), 511a-512a, 2022 | 1 | 2022 |
| fcell-11-1302585. pdf V Hambardikar, Y Akosah, ER Scoma, M Guitart-Mampel, P Urquiza, ... Health Research Alliance, 2024 | | 2024 |
| Abnormal concentration of porphyrins in serum from COVID-19 patients (vol 190, pg e265, 2020) I San Juan, C Bruzzone, M Bizkarguenaga, G Bernardo-Seisdedos, ... BRITISH JOURNAL OF HAEMATOLOGY 193 (2), 429-429, 2021 | | 2021 |
| Use of ciclopirox as modulator of heme group biosynthesis and in the treatment of porphyria and other diseases. O Millet Aguilar-Galindo, JM Falcon Perez, J Catilla Catrillon, ... | | 2018 |
| Confirmation and approval by the U.S. Food & Drug Administration of Ciclopirox as an Orphan-Drug for treatment of congenital erythropoietic porphyria. | | 2018 |
| Ciclopirox as an Orphan Medicinal Product for the treatment of congenital erythropoietic porphyria | | 2018 |
